International Assets Investment Management LLC Acquires 14,828 Shares of Natera, Inc. (NASDAQ:NTRA)

International Assets Investment Management LLC raised its stake in shares of Natera, Inc. (NASDAQ:NTRA) by 9,755.3% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 14,980 shares of the medical research company’s stock after acquiring an additional 14,828 shares during the quarter. International Assets Investment Management LLC’s holdings in Natera were worth $1,902,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also made changes to their positions in NTRA. GAMMA Investing LLC boosted its position in Natera by 32.7% during the third quarter. GAMMA Investing LLC now owns 430 shares of the medical research company’s stock valued at $55,000 after purchasing an additional 106 shares in the last quarter. Moss Adams Wealth Advisors LLC grew its holdings in Natera by 5.4% in the third quarter. Moss Adams Wealth Advisors LLC now owns 2,646 shares of the medical research company’s stock worth $336,000 after purchasing an additional 135 shares during the last quarter. Private Advisor Group LLC increased its position in shares of Natera by 5.2% during the third quarter. Private Advisor Group LLC now owns 2,721 shares of the medical research company’s stock worth $346,000 after purchasing an additional 135 shares in the last quarter. Quarry LP lifted its holdings in shares of Natera by 148.4% during the 2nd quarter. Quarry LP now owns 318 shares of the medical research company’s stock valued at $34,000 after purchasing an additional 190 shares during the last quarter. Finally, Itau Unibanco Holding S.A. acquired a new stake in shares of Natera in the 2nd quarter worth $28,000. 99.90% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In related news, insider Jonathan Sheena sold 2,700 shares of the business’s stock in a transaction on Monday, August 12th. The shares were sold at an average price of $113.82, for a total value of $307,314.00. Following the completion of the sale, the insider now owns 299,441 shares of the company’s stock, valued at approximately $34,082,374.62. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, insider Jonathan Sheena sold 2,700 shares of Natera stock in a transaction dated Monday, August 12th. The stock was sold at an average price of $113.82, for a total value of $307,314.00. Following the sale, the insider now directly owns 299,441 shares in the company, valued at approximately $34,082,374.62. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO Steven Leonard Chapman sold 5,583 shares of the stock in a transaction that occurred on Thursday, August 15th. The shares were sold at an average price of $118.91, for a total value of $663,874.53. Following the transaction, the chief executive officer now directly owns 200,710 shares of the company’s stock, valued at $23,866,426.10. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 50,164 shares of company stock worth $6,157,291 in the last quarter. Corporate insiders own 7.60% of the company’s stock.

Analyst Upgrades and Downgrades

NTRA has been the subject of a number of research analyst reports. Sanford C. Bernstein increased their price target on Natera from $125.00 to $135.00 and gave the company an “outperform” rating in a research note on Wednesday, October 30th. UBS Group dropped their target price on shares of Natera from $160.00 to $145.00 and set a “buy” rating on the stock in a research report on Friday, August 9th. StockNews.com cut shares of Natera from a “hold” rating to a “sell” rating in a report on Friday, October 25th. Canaccord Genuity Group boosted their price objective on shares of Natera from $145.00 to $150.00 and gave the company a “buy” rating in a report on Tuesday, October 29th. Finally, The Goldman Sachs Group raised their target price on Natera from $125.00 to $140.00 and gave the stock a “buy” rating in a research note on Wednesday, October 16th. One research analyst has rated the stock with a sell rating and sixteen have issued a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $125.69.

Natera Trading Up 2.6 %

Shares of Natera stock opened at $124.16 on Monday. The firm has a 50-day simple moving average of $123.40 and a two-hundred day simple moving average of $112.38. The company has a debt-to-equity ratio of 0.34, a quick ratio of 4.01 and a current ratio of 4.14. Natera, Inc. has a fifty-two week low of $40.17 and a fifty-two week high of $133.54. The company has a market cap of $15.36 billion, a P/E ratio of -50.68 and a beta of 1.53.

Natera (NASDAQ:NTRA) last released its quarterly earnings results on Thursday, August 8th. The medical research company reported ($0.30) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.69) by $0.39. The company had revenue of $413.35 million during the quarter, compared to analysts’ expectations of $343.00 million. Natera had a negative return on equity of 36.74% and a negative net margin of 21.47%. Natera’s quarterly revenue was up 58.1% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.97) EPS. As a group, equities analysts predict that Natera, Inc. will post -1.96 earnings per share for the current fiscal year.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.